Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 18, 2022

Primary Completion Date

January 22, 2025

Study Completion Date

January 22, 2025

Conditions
Growth Hormone Deficiency
Interventions
DRUG

LUM-201

Administered orally once daily

Trial Locations (10)

20010

Children's National Hospital, Washington D.C.

22908

University of Virginia Health System, Charlottesville

43205

Nationwide Children's Hospital, Columbus

46202

Indiana University School of Medicine, Indianapolis

55454

M Health, Fairview Pediatric Specialty Clinics- Discovery Clinic, Minneapolis

64111

The Children's Mercy Hospital, Kansas City

92123

Rady Children's Hospital, San Diego

Unknown

Klinika Endokrynologii i Chorob Metabolicznych, Instytut Centrum Zdrowia Matki Polki, Lodz

Sonomed - Centrum Medyczne, Szczecin

"Klinika Endokrynologii i Diabetologii, Instytut Pomnik Centrum Zdrowia Dziecka", Warsaw

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Lumos Pharma

INDUSTRY